Enith-MACENCT07918846
A Clinical Study Testing Enicepatide in Participants Living With Overweight or Obesity and Cardiovascular Disease
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
Time to First Occurrence of Any Component of 5-point (5P) MACE
Timeframe: From randomization up to 4.2 years
Secondary (39)
Time to First Occurrence of Any Component of 3-point (3P) MACE
Time to New-Onset T2DM
Total Occurrence of All-Cause Hospitalization
Time to Death From Any Cause
Time to CV Death
Show 34 moreShow less
Incidence and Severity of Adverse Events
Time to First Occurrence of Any Component of 4-point (4P) MACE
Time to First Occurrence of HHF, Urgent HF Visit, or CV Death
Time to First Occurrence of HHF, Urgent HF Visit, or All-Cause Mortality
Change From Baseline in Health-Related Quality of Life (HRQoL) as Assessed by the Short Form 36 Health Survey Version 2.0 (SF-36 V2) Acute Form Physical Functioning Domain Score
Change From Baseline in HRQoL as Assessed by the SF-36 V2 Acute Form Role-Physical Domain Score
Change From Baseline in HRQoL as Assessed by the SF-36 V2 Acute Form Bodily Pain Domain Score
Change From Baseline in HRQoL as Assessed by the SF-36 V2 Acute Form General Health Domain Score
Change From Baseline in HRQoL as Assessed by the SF-36 V2 Acute Form Vitality Domain Score
Change From Baseline in HRQoL as Assessed by the SF-36 V2 Acute Form Social Functioning Domain Score
Change From Baseline in HRQoL as Assessed by the SF-36 V2 Acute Form Role-Emotional Domain Score
Change From Baseline in HRQoL as Assessed by the SF-36 V2 Acute Form Mental Health Domain Score
Change From Baseline in HRQoL as Assessed by the SF-36 V2 Acute Form Physical Component Summary Score
Change From Baseline in HRQoL as Assessed by the SF-36 V2 Acute Form Mental Component Summary Score
Change From Baseline in Health Status as Assessed by the EuroQol-5 Dimensions 5-Level (EQ-5D-5L) Score
Time To First Occurrence of Sustained ≥40% Estimated Glomerular Filtration Rate (eGFR) Decline From Baseline, End Stage Kidney Disease (ESKD), or Renal Death
Change From Baseline in Body Weight
Change From Baseline in Waist Circumference
Change From Baseline in Waist-to-Height Ratio
Change From Baseline in Systolic Blood Pressure
Change From Baseline in Diastolic Blood Pressure
Change From Baseline in Heart Rate
Change From Baseline in Double Product
Change From Baseline in Pulse Pressure
Change From Baseline in Mean Arterial Pressure
Change From Baseline in Total Cholesterol
Change From Baseline in Non-High-Density Lipoprotein (HDL)
Change From Baseline in Low-Density Lipoprotein (LDL)
Change From Baseline in HDL
Change From Baseline in Triglycerides (TG)
Change From Baseline in Very-low-Density Lipoprotein (vLDL)
Change From Baseline in Hemoglobin A1c (HbA1c)
Change From Baseline in High-Sensitivity C-Reactive Protein (hs-CRP)
Change From Baseline in N-Terminal pro-B-Type Natriuretic Peptide (NT-proBNP)
Arms and interventions
Arm 1: PlaceboPlacebo comparator
Participants will receive volume-matched placebo.
Arm 2: EnicepatideExperimental
Participants will receive enicepatide.
Combination products: Enicepatide, Placebo